000153699 001__ 153699
000153699 005__ 20251017144649.0
000153699 0247_ $$2doi$$a10.1016/j.medj.2024.10.020
000153699 0248_ $$2sideral$$a143491
000153699 037__ $$aART-2025-143491
000153699 041__ $$aeng
000153699 100__ $$0(orcid)0000-0002-8026-7391$$aPazo-Cid, Roberto$$uUniversidad de Zaragoza
000153699 245__ $$aIntegrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?
000153699 260__ $$c2025
000153699 5060_ $$aAccess copy available to the general public$$fUnrestricted
000153699 5203_ $$aThe treatment of locally advanced gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma remains a significant challenge despite advances in chemotherapy (ChT) and surgical techniques. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant (NAT) and perioperative treatment regimens is a promising step toward improving outcomes for this patient population.
The phase 2 study reported by Long et al.1 explores the combination of the novel bispecific anti-PD-1/CTLA-4 antibody
000153699 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000153699 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000153699 700__ $$aGomila Pons, Paula
000153699 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000153699 773__ $$g6, 3 (2025), 100543 [5 p.]$$tMed$$x2666-6359
000153699 8564_ $$s248621$$uhttps://zaguan.unizar.es/record/153699/files/texto_completo.pdf$$yPostprint
000153699 8564_ $$s1120961$$uhttps://zaguan.unizar.es/record/153699/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000153699 909CO $$ooai:zaguan.unizar.es:153699$$particulos$$pdriver
000153699 951__ $$a2025-10-17-14:35:39
000153699 980__ $$aARTICLE